Back

One-year results from the FLXibility post-approval study: final real-world clinical outcomes with a next-generation left atrial appendage closure device

4 April 2022 (13:00 - 13:30)
Organised by:
Congress Presentation Part of: Moderated ePosters - How to optimise stroke prevention in atrial fibrillation Left Atrial Appendage Closure EHRA Premium Access EHRA 2022

About the speaker

Photo
Professor Timothy Betts

Oxford University Hospitals NHS Trust, Oxford (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Impact of P-glycoprotein and/or CYP3A4-interacting drugs on the risk-benefit profile of NOACs in patients with atrial fibrillation: a meta-analysis
Mr M. Grymonprez (Gent, BE)
Abstract Slides
Presentation thumbnail
Prevalence and outcomes of hypoattenuation defects and appendage patency on computed tomography after left atrial appendage closure
Professor H. Cochet (Bordeaux, FR)
Abstract Slides
Presentation thumbnail
Single versus dual antiplatelet therapy following transcatheter left atrial appendage closure
Doctor A. Sabbag (Ramat Gan, IL)

Access the full session

Session thumbnail
Moderated ePosters - How to optimise stroke prevention in atrial fibrillation

The Event

Event poster

EHRA 2022

4 April 2022 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Left atrial appendage closure in atrial fibrillation: gaps in knowledge
thumbnail
Congress Session
Stroke prevention in atrial fibrillation: do not forget the left atrial appendage!
thumbnail
Congress Session
LAAC and AF ablation are evolving, are you?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources